Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
Conclusions</div>The risk of pemetrexed-related ILD is similar level as other anti-cancer drugs under clinical settings. Careful observations continuously during and at least for 2 months after the last administration of pemetrexed are advised.</span>
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | CT Scan | Interstitial Lung Disease | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Pneumonia | Smokers | Study | Toxicology